The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Cannabis use and risk of schizophrenia: a Mendelian randomization study
Open accessAbstract
Cannabis use is observationally associated with an increased risk of schizophrenia, but whether the relationship is causal is not known. Using a genetic approach, we took 10 independent genetic variants previously identified to associate with cannabis use in 32 330 individuals to determine the nature of the association between cannabis use and risk of schizophrenia. Genetic variants were employed as instruments to recapitulate a randomized controlled trial involving two groups (cannabis users vs nonusers) to estimate the causal effect of cannabis use on risk of schizophrenia in 34 241 cases and 45 604 controls from predominantly European descent. Genetically-derived estimates were compared with a meta-analysis of observational studies reporting ever use of cannabis and risk of schizophrenia or related disorders. Based on the genetic approach, use of cannabis was associated with increased risk of schizophrenia (odds ratio (OR) of schizophrenia for users vs nonusers of cannabis: 1.37; 95% confidence interval (CI), 1.09-1.67; P-value=0.007). The corresponding estimate from observational analysis was 1.43 (95% CI, 1.19-1.67; P-value for heterogeneity =0.76). The genetic markers did not show evidence of pleiotropic effects and accounting for tobacco exposure did not alter the association (OR of schizophrenia for users vs nonusers of cannabis, adjusted for ever vs never smoker: 1.41; 95% CI, 1.09-1.83). This adds to the substantial evidence base that has previously identified cannabis use to associate with increased risk of schizophrenia, by suggesting that the relationship is causal. Such robust evidence may inform public health messages about cannabis use, especially regarding its potential mental health consequences.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sudlow, C., Gallacher, J., Allen, N., Beral, V., Burton, P., Danesh, J., Downey, P., Elliott, P., Green, J., Landray, M., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001779 · Cited by 12,728
Self-citationBowden, J., Davey Smith, G., & Burgess, S. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv080 · Cited by 9,816 · cited 3×
“We tested for presence of unmeasured pleiotropy of the genetic instruments using MR-Egger as described by Bowden et al.(11) Essentially, this uses the same principles of testing”
InfluentialBowden, J., Davey Smith, G., Haycock, P. C., & Burgess, S. (2016) · Genetic Epidemiology · doi:10.1002/gepi.21965 · Cited by 8,922
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Biological insights from 108 schizophrenia-associated genetic loci
Schizophrenia Working Group of the Psychiatric Genomics Consortium (2014) · Nature · doi:10.1038/nature13595 · Cited by 7,577
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
Self-citationMendelian Randomization Analysis With Multiple Genetic Variants Using Summarized Data
Burgess, S., Butterworth, A., & Thompson, S. G. (2013) · Genetic Epidemiology · doi:10.1002/gepi.21758 · Cited by 6,050
Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review.
Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61162-3 · Cited by 2,224
Owen, M. J., Sawa, A., & Mortensen, P. B. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01121-6 · Cited by 1,870
A review of instrumental variable estimators for Mendelian randomization
Burgess, S., Small, D. S., & Thompson, S. G. (2017) · Statistical Methods in Medical Research · doi:10.1177/0962280215597579 · Cited by 1,764
Cited by
Skrivankova, V. W., Richmond, R. C., Woolf, B. A. R., Yarmolinsky, J., Davies, N. M., Swanson, S. A., VanderWeele, T. J., Higgins, J. P. T., Timpson, N. J., Dimou, N., et al. (2021) · JAMA · doi:10.1001/jama.2021.18236 · Cited by 3,994
Recent Developments in Mendelian Randomization Studies
Zheng, J., Baird, D., Borges, M.-C., Bowden, J., Hemani, G., Haycock, P., Evans, D. M., & Smith, G. D. (2017) · Current Epidemiology Reports · doi:10.1007/s40471-017-0128-6 · Cited by 1,147
Burgess, S., & Labrecque, J. A. (2018) · European Journal of Epidemiology · doi:10.1007/s10654-018-0424-6 · Cited by 569
the 23andMe Research Team, Pasman, J. A., The Substance Use Disorders Working Group of the Psychiatric Genomics Consortium, International Cannabis Consortium, Verweij, K. J. H., Gerring, Z., Stringer, S., Sanchez-Roige, S., Treur, J. L., Abdellaoui, A., et al. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0206-1 · Cited by 498
Psychiatric genetics and the structure of psychopathology
Smoller, J. W., Andreassen, O. A., Edenberg, H. J., Faraone, S. V., Glatt, S. J., & Kendler, K. S. (2019) · Molecular Psychiatry · doi:10.1038/s41380-017-0010-4 · Cited by 398
Associations Between Prenatal Cannabis Exposure and Childhood Outcomes: Results From the ABCD Study
Paul, S. E., Hatoum, A. S., Fine, J. D., Johnson, E. C., Hansen, I., Karcher, N. R., Moreau, A. L., Bondy, E., Qu, Y., Carter, E. B., et al. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.2902 · Cited by 329
The link between schizophrenia and substance use disorder: A unifying hypothesis
Khokhar, J. Y., Dwiel, L. L., Henricks, A. M., Doucette, W. T., & Green, A. I. (2018) · Schizophrenia Research · doi:10.1016/j.schres.2017.04.016 · Cited by 281
Campeny, E., López-Pelayo, H., Nutt, D., Blithikioti, C., Oliveras, C., Nuño, L., Maldonado, R., Florez, G., Arias, F., Fernández-Artamendi, S., et al. (2020) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2020.02.003 · Cited by 127
Musliner, K. L., & Østergaard, S. D. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12869 · Cited by 79
Schaefer, J. D., Hamdi, N. R., Malone, S. M., Vrieze, S., Wilson, S., McGue, M., & Iacono, W. G. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2013180118 · Cited by 64
Gillespie, N. A., & Kendler, K. S. (2021) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.3564 · Cited by 54
Adverse effects of heavy cannabis use: Even plants can harm the brain
Sideli, L., Trotta, G., Spinazzola, E., La Cascia, C., & Di Forti, M. (2021) · Pain · doi:10.1097/j.pain.0000000000001963 · Cited by 36
Schizophrenia and substance use comorbidity: a genome-wide perspective
Polimanti, R., Agrawal, A., & Gelernter, J. (2017) · Genome Medicine · doi:10.1186/s13073-017-0423-3 · Cited by 24
“reported that the top ten loci from a GWAS of cannabis use were associated with an increased risk of schizophrenia, when tobacco exposure and pleiotropy were taken into account [7].”
Use of Guanfacine for Cannabis Use Disorder and Related Symptomology
Holst, M., Mathai, D. S., Patel, M. M., Rodgman, C., Keller, J., Hussain, M. Z., De La Garza, R., Kosten, T. R., & Verrico, C. D. (2019) · The American Journal on Addictions · doi:10.1111/ajad.12959 · Cited by 5
Metadata
- Authors
- Vaucher, J., Keating, B. J., Lasserre, A. M., Gan, W., Lyall, D. M., Ward, J., Smith, D. J., Pell, J. P., Sattar, N., Paré, G., & Holmes, M. V.
- Venue
- Molecular Psychiatry
- Published
- 2017-01-24
- Volume
- 23
- Issue
- 5
- Pages
- 1287-1292
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2582094868
- Cited by
- 260
- References
- 40
- FWCI
- 12.92
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.